Contents

Terlipressin

Chemical compound

Terlipressin

Clinical data
Trade names	Terlivaz
AHFS/Drugs.com	International Drug Names
Routes of administration	Intravenous
ATC code	H01BA04 (WHO)
Legal status
Legal status	US: WARNING[1]Rx-only[2][3]
Pharmacokinetic data
Protein binding	~30%
Identifiers
IUPAC name 1-{[(4R,7S,10S,13S,16S,19R)-19-{[({[(aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-N-(2-amino-2-oxoethyl)-L-lysinamide
CAS Number	14636-12-5 Y
PubChem CID	72081
DrugBank	DB02638 Y
ChemSpider	65067 Y
UNII	7Z5X49W53P
KEGG	D06672 Y
CompTox Dashboard (EPA)	DTXSID7048952
ECHA InfoCard	100.035.149
Chemical and physical data
Formula	C52H74N16O15S2
Molar mass	1227.38 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(N)CNC(=O)[C@@H](NC(=O)[C@H]4N(C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1)Cc2ccc(O)cc2)Cc3ccccc3)CCC(=O)N)CC(=O)N)CCC4)CCCCN
InChI InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1 Y Key:BENFXAYNYRLAIU-QSVFAHTRSA-N Y
(verify)

Terlipressin, sold under the brand name Terlivaz among others, is an analogueofvasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopressin receptor agonist.^[2]

Terlipressin was approved for medical use in the United States in 2022.^[2][4][5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[5][6]

Medical uses[edit]

Terlipressin is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.^[2]

Indications for use include norepinephrine-resistant septic shock^[7] although, 2021 Surviving Sepsis Guidelines recommend against its use for adults with septic shock^[8] and hepatorenal syndrome.^[9] In addition, it is used to treat bleeding esophageal varices.^[10]

Contraindications[edit]

Terlipressin is contraindicated in people experiencing hypoxia or worsening respiratory symptoms and in people with ongoing coronary, peripheral or mesenteric ischemia.^[2] Terlipressin may cause fetal harm when used during pregnancy.^[2]

Society and culture[edit]

Terlipressin is available in United States,^[11] New Zealand,^[12] Australia, the European Union,^[13] India, Pakistan & UAE. It is sold under various brand names including Glypressin and Terlivaz.

References[edit]

^ ^{a b} "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

^ New Drug Therapy Approvals 2022 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.

External links[edit]

• "Terlipressin". Drug Information Portal. U.S. National Library of Medicine.